NASDAQ:ONVOOrganovo Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Organovo Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.77 +0.05 (+6.66 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$0.73Now: $0.77▼$0.7850-Day Range$0.48MA: $0.62▼$0.7952-Week Range$0.19Now: $0.77▼$0.93Volume1.19 million shsAverage Volume1.14 million shsMarket Capitalization$100.17 millionP/E RatioN/ADividend YieldN/ABeta1.19 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Organovo. Previous Next 2.5 Community Rank Outperform VotesOrganovo has received 192 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrganovo has received 190 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrganovo has received 50.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote “Outperform” if you believe ONVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrganovo does not currently pay a dividend.Dividend GrowthOrganovo does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Organovo insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Organovo is held by insiders.Percentage Held by Institutions50.06% of the stock of Organovo is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Organovo is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organovo is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganovo has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONVO Previous Symbol CUSIPN/A CIK1497253 Webwww.organovo.com Phone858-224-1000Debt Debt-to-Equity RatioN/A Current Ratio15.65 Quick Ratio15.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.20 million Price / Sales45.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book3.83Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-18,710,000.00 Net Margins-798.68% Return on Equity-60.96% Return on Assets-53.10%Miscellaneous Employees70 Outstanding Shares130,618,000Market Cap$100.17 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable $0.77 +0.05 (+6.66 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ONVO News and Ratings via Email Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Organovo (NASDAQ:ONVO) Frequently Asked Questions How has Organovo's stock been impacted by COVID-19 (Coronavirus)? Organovo's stock was trading at $0.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONVO shares have increased by 195.0% and is now trading at $0.7669. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Organovo? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo. When is Organovo's next earnings date? Organovo is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Organovo. How were Organovo's earnings last quarter? Organovo Holdings Inc (NASDAQ:ONVO) announced its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). The medical research company earned $0.67 million during the quarter, compared to analyst estimates of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 60.96%. View Organovo's earnings history. Has Organovo been receiving favorable news coverage? Headlines about ONVO stock have trended somewhat negative this week, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Organovo. Are investors shorting Organovo? Organovo saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,380,000 shares, an increase of 12.2% from the July 15th total of 1,230,000 shares. Based on an average trading volume of 1,640,000 shares, the short-interest ratio is presently 0.8 days. Approximately 1.1% of the shares of the company are sold short. View Organovo's Current Options Chain. Who are some of Organovo's key competitors? Some companies that are related to Organovo include Voyager Therapeutics (VYGR), Scholar Rock (SRRK), PDL BioPharma (PDLI), Brainstorm Cell Therapeutics (BCLI), Precision BioSciences (DTIL), ADMA Biologics (ADMA), Harpoon Therapeutics (HARP), Cabaletta Bio (CABA), Eiger Biopharmaceuticals (EIGR), DBV TECHNOLOGIE/S (DBVT), Cellular Biomedicine Group (CBMG), Pluristem Therapeutics (PSTI), Dyadic International (DYAI), CASI Pharmaceuticals (CASI) and Fennec Pharmaceuticals (FENC). View all competitors. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Novavax (NVAX), Exelixis (EXEL), Anavex Life Sciences (AVXL), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Organovo's key executives? Organovo's management team includes the following people: Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)Mr. Craig Kussman, Chief Financial Officer (Age 60)Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)Mr. Paul Gallant, Gen. Mang. (Age 54)Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications What is Organovo's stock symbol? Organovo trades on the NASDAQ under the ticker symbol "ONVO." Who are Organovo's major shareholders? Organovo's stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (7.50%), WINTON GROUP Ltd (0.18%) and UBS Group AG (0.07%). View institutional ownership trends for Organovo. Which major investors are selling Organovo stock? ONVO stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., and WINTON GROUP Ltd. View insider buying and selling activity for Organovo. Which major investors are buying Organovo stock? ONVO stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Organovo. How do I buy shares of Organovo? Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Organovo's stock price today? One share of ONVO stock can currently be purchased for approximately $0.77. How big of a company is Organovo? Organovo has a market capitalization of $100.17 million and generates $2.20 million in revenue each year. Organovo employs 70 workers across the globe. What is Organovo's official website? The official website for Organovo is www.organovo.com. How can I contact Organovo? Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
